SRC and melanoma: Taken together, these results indicated that integrin/Src/YAP1 axis mediated resistance to MAPK and PI3K/mTOR dual inhibitors, which made it a promising target for the development of combinatorial regimens overcoming MAPK and PI3K/mTOR dual inhibitors–refractory melanoma patients.